Chapel Hill-based University of North Carolina Lineberger Comprehensive Cancer Center has been awarded up to $28 million to develop an adaptive clinical trial targeting metastatic breast cancer. The trial is part of the Advanced Research Projects Agency for Health’s Advanced Analysis for Precision Cancer Therapy program, also called ADAPT. Other ADAPT awardees and their trial […]| Becker's Hospital Review | Healthcare News & Analysis
Naim Rashid, PhD, engages in collaborative studies at UNC Lineberger, working on problems relating to genomics and clinical studies.| UNC Lineberger
Chuck Perou researches identifying the drivers of metastatic disease and the role of the adaptive immune system in breast tumor progression.| UNC Lineberger